Humana (NYSE:HUM) Shares Gap Down – Should You Sell?

Humana Inc. (NYSE:HUM)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $229.72, but opened at $217.19. Humana shares last traded at $223.31, with a volume of 555,450 shares trading hands.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Q1 earnings and revenue beat and membership growth — Humana posted EPS of $10.31 (above estimates) and revenue growth driven by premium and Medicare Advantage membership gains, supporting near‑term cash flow and scale benefits. Humana Beats Q1 Earnings Estimates on Increasing Premiums
• Positive Sentiment: On track for rapid Medicare Advantage membership expansion — Management says Humana is on track for ~25% MA membership growth, which improves long‑term revenue runway and leverage if margins recover. Humana on track for 25% growth in Medicare Advantage membership
• Positive Sentiment: Profitability still meaningful — Coverage pieces note quarterly profit remained above $1B as Medicare costs eased slightly, reinforcing that the business can generate sizable earnings even amid cost pressure. Humana Profits Eclipse $1 Billion As Medicare Costs Ease Slightly
• Neutral Sentiment: Analysts keep a cautious stance — Deutsche Bank raised its Humana price target to $235 but maintained a hold rating, reflecting mixed conviction; broader analyst consensus remains a “Hold.” These moves provide calibration but not a clear buy signal. Deutsche Bank adjusts Humana price target to $235 from $180; maintains hold rating
• Neutral Sentiment: Consensus rating unchanged — Multiple outlets report a consensus “Hold” from analysts, indicating the market is waiting for clearer margin recovery or CMS rate changes before committing. Humana Inc. Given Consensus Rating of “Hold” by Analysts
• Negative Sentiment: Medicare Star ratings decline pressured outlook — Management left FY2026 guidance largely unchanged and cited reduced MA Star ratings as a headwind to near‑term profitability, which disappointed investors despite the beat. Humana 2026 outlook unchanged due to Star ratings decline
• Negative Sentiment: Regulatory/reimbursement pressure flagged — Company warned Medicare payments are not keeping pace with costs and emphasized that margin recovery is a priority, signaling continued near‑term earnings pressure until CMS relief or cost fixes arrive. Humana Warns Medicare Payments Won’t Keep Up With Costs

Analyst Ratings Changes

A number of analysts have commented on HUM shares. Raymond James Financial cut their price objective on shares of Humana from $340.00 to $230.00 and set an “outperform” rating for the company in a report on Friday, February 13th. JPMorgan Chase & Co. cut their price objective on shares of Humana from $274.00 to $180.00 and set a “neutral” rating for the company in a report on Friday, February 13th. Zacks Research downgraded shares of Humana from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 14th. Evercore increased their price objective on shares of Humana from $180.00 to $195.00 in a report on Wednesday, April 8th. Finally, TD Cowen cut their price objective on shares of Humana from $260.00 to $173.00 and set a “hold” rating for the company in a report on Friday, February 13th. Seven research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, Humana currently has a consensus rating of “Hold” and a consensus target price of $233.39.

Humana Price Performance

The stock’s fifty day moving average price is $188.41 and its 200-day moving average price is $227.52. The firm has a market cap of $28.44 billion, a price-to-earnings ratio of 25.33, a P/E/G ratio of 2.61 and a beta of 0.44. The company has a current ratio of 1.77, a quick ratio of 2.00 and a debt-to-equity ratio of 0.66.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. The business had revenue of $39.65 billion during the quarter, compared to the consensus estimate of $39.37 billion. Humana had a net margin of 0.82% and a return on equity of 10.45%. The business’s revenue was up 23.5% compared to the same quarter last year. During the same quarter last year, the firm earned $11.58 EPS. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, equities research analysts forecast that Humana Inc. will post 9.03 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.5%. The ex-dividend date is Friday, June 26th. Humana’s dividend payout ratio (DPR) is 36.05%.

Insiders Place Their Bets

In related news, insider Sanjay K. Shetty bought 810 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was purchased at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the acquisition, the insider owned 11,657 shares of the company’s stock, valued at approximately $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.20% of the company’s stock.

Institutional Trading of Humana

Institutional investors have recently added to or reduced their stakes in the stock. Montag A & Associates Inc. increased its holdings in Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after purchasing an additional 94 shares during the last quarter. CoreCap Advisors LLC increased its holdings in Humana by 54.4% in the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 37 shares during the last quarter. Fideuram Asset Management Ireland dac acquired a new stake in Humana in the 4th quarter valued at approximately $27,000. Reflection Asset Management acquired a new stake in Humana in the 4th quarter valued at approximately $29,000. Finally, Rosenberg Matthew Hamilton increased its holdings in Humana by 136.0% in the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after purchasing an additional 68 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.